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Abstract
Background: The interferon-γ (IFN-γ)-inducible immunity-related GTPase (IRG), Irgm1, plays an essential role in
restraining activation of the IRG pathogen resistance system. However, the loss of Irgm1 in mice also causes a
dramatic but unexplained susceptibility phenotype upon infection with a variety of pathogens, including many not
normally controlled by the IRG system. This phenotype is associated with lymphopenia, hemopoietic collapse, and
death of the mouse.
Results: We show that the three regulatory IRG proteins (GMS sub-family), including Irgm1, each of which localizes
to distinct sets of endocellular membranes, play an important role during the cellular response to IFN-γ, each
protecting specific membranes from off-target activation of effector IRG proteins (GKS sub-family). In the absence of
Irgm1, which is localized mainly at lysosomal and Golgi membranes, activated GKS proteins load onto lysosomes,
and are associated with reduced lysosomal acidity and failure to process autophagosomes. Another GMS protein,
Irgm3, is localized to endoplasmic reticulum (ER) membranes; in the Irgm3-deficient mouse, activated GKS proteins
are found at the ER. The Irgm3-deficient mouse does not show the drastic phenotype of the Irgm1 mouse. In the
Irgm1/Irgm3 double knock-out mouse, activated GKS proteins associate with lipid droplets, but not with lysosomes,
and the Irgm1/Irgm3−/− does not have the generalized immunodeficiency phenotype expected from its Irgm1
deficiency.
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Conclusions: The membrane targeting properties of the three GMS proteins to specific endocellular membranes
prevent accumulation of activated GKS protein effectors on the corresponding membranes and thus enable GKS
proteins to distinguish organellar cellular membranes from the membranes of pathogen vacuoles. Our data suggest
that the generalized lymphomyeloid collapse that occurs in Irgm1−/− mice upon infection with a variety of
pathogens may be due to lysosomal damage caused by off-target activation of GKS proteins on lysosomal
membranes and consequent failure of autophagosomal processing.
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Background
The identification and eradication of intracellular para-
sites that are enclosed in host-derived vacuolar mem-
branes poses the question, how are these new structures
to be distinguished from endogenous membrane-bound
cytoplasmic organelles? The issue is especially acute for
organisms such as Toxoplasma gondii, which do not
enter cells via the phagosomal route, but rather by an
active entry mechanism independent of all host uptake
machinery. In mice, resistance to such pathogens is
dependent on the interferon-γ (IFN-γ)-inducible system
of immunity-related GTPases (IRG proteins) [1, 2]. The
effector proteins of this system rapidly accumulate and
activate at the vacuolar membranes of a disparate group
of intracellular parasites, namely the protozoan T. gondii
[3–9], the bacterium Chlamydia trachomatis [10–13],
and the microsporidian fungus Encephalitozoon cuniculi
[14], but not at the membranes of many other intracellu-
lar organisms. The known target organisms all share the
property of entering host cells by non-phagocytic mech-
anisms. The accumulation of activated IRG proteins on
the cytosolic face specifically of parasitophorous vacuole
membranes (PVMs) seems to imply that these
membrane-bound structures are distinct from endogen-
ous membrane-bound intracellular compartments, but
the mechanism by which IRG proteins activate only on
pathogen-containing vacuoles is not fully understood.
In 2004, Martens [15] hypothesized that activation at
endogenous membranes is inhibited by the presence of
negative regulatory self-proteins (designated X) that
block the activation of IRG proteins on these mem-
branes (Fig. 1).
In this proposal, X proteins are missing on newly
formed pathogen-containing vacuoles, such as those of
T. gondii, thus allowing IRG proteins to activate and
concentrate on this compartment. We subsequently
showed [16] that a structurally distinct subset of three
IRG proteins, the IRGM or GMS subset, fulfill the defin-
ition of X. The GMS subset are restricted to specific
organellar compartments [17, 18], they inhibit the acti-
vation of the effector (GKS) subset of IRG proteins by
blocking nucleotide exchange, and they are either absent
or very weakly expressed on T. gondii PVMs [19]. In
their absence, effector GKS proteins activate spontan-
eously in the cytoplasm. This model has been reiterated
in subsequent publications from our laboratory [20], and
recently restated as “missing self” from another labora-
tory [21, 22].
The GMS proteins are tightly associated with distinct
compartments of the cellular endomembrane system. In
uninfected cells, Irgm1 localizes strongly to the Golgi
apparatus [17, 23, 24] but also to the endolysosomal
compartment [23, 25], mitochondria [24, 26, 27], peroxi-
somes [21, 24], and to lipid droplets [21]. Irgm1 is also
found on phagocytic cups containing latex beads and on
sterile phagosomes containing ferritin and latex beads
[17, 23, 25]. However, contrary to earlier claims based
on organelle purification [28] or transfected, tagged con-
structs [29, 30], Irgm1 is not detectably present on either
listerial or mycobacterial phagosomes [27]. Irgm2 local-
izes to the Golgi [18] and Irgm3 to the endoplasmic
reticulum (ER) [17, 31, 32] and lipid droplets [32] and
has been reported on magnetically purified latex bead
phagosomes [23]. In IFN-γ-induced wild type (WT)
cells, the effector (GKS) IRG proteins are predominantly
cytosolic and in the inactive GDP-bound state [33]. All
three GMS regulators are required for the control of
GKS activation in the cell: when GKS proteins are
expressed in the cell in the absence of one or more
GMS proteins, they activate spontaneously, form
aggregate-like structures, and do not accumulate on the
T. gondii PVM [8, 16, 17].
Until now, disruptions of Irgm1 and Irgm3 have been
described [3, 4]. Loss of Irgm3 results in a specific loss
of function against just that subset of parasites listed
above that seem to be the focus of the IRG resistance
mechanism [3, 4]. Loss of Irgm1, on the other hand, has
a drastic phenotype severely weakening mouse resistance
to a number of pathogens, not only to T. gondii, C. tra-
chomatis, and E. cuniculi, but also to pathogens that are
not controlled by GKS proteins such as Listeria [4, 9],
Mycobacterium [24, 28, 34, 35], Salmonella [6], Leish-
mania [36], and Trypanosoma [37]. Irgm1−/− mice are
also reported to be unusually susceptible to lipopolysac-
charide injection [38], in the mouse model of colitis [39],
in experimental immune encephalitis [40, 41], and in the
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mouse model of stroke [42]. Due to the complexity of
this phenotype, very different and sometimes contradict-
ory functions have been attributed to Irgm1 [20, 35, 43,
44]. In an infection setting, it is clear that Irgm1 cannot
exert a direct effector action on phagosomes or PVMs
because, despite earlier claims [24, 28–30], Irgm1 is not
present on pathogen-containing phagosomal or vacuolar
membranes [27]. Whatever action it performs in the
control of infection must therefore be indirect. The im-
mune defect in Irgm1−/− mice appears to follow at least
in part from a severe defect in their hematopoietic stem
cells (HSCs), which lack renewal capacity [45]. Infection
of Irgm1−/− mice with any pathogen that stimulates IFN-
γ induction, for instance Salmonella typhimurium [46]
or Mycobacterium avium [34], results in a generalized
lymphomyeloid collapse [35, 47]. Additionally, memory
T cells from Irgm1-deficient mice have an IFN-γ-
dependent proliferation defect following antigen restim-
ulation and a large proportion of restimulated cells die
[35]. In view of the severe phenotype of the Irgm1
mouse, it was therefore a great surprise when it was
shown that the double mutant Irgm1/Irgm3−/− mouse re-
verts back to the limited and precise phenotypic defi-
ciency of the Irgm3−/− single mutant [6]. Thus, the
drastic defect of Irgm1 deficiency is somehow repaired
by additional Irgm3 deficiency. This striking result fur-
ther contradicts any direct anti-pathogenic effector
model of Irgm1 action, leaving the severe cellular defects
of the Irgm1-deficient mouse in need of an explanation
that satisfies these paradoxical data.
Since GMS proteins maintain GKS proteins in the
GDP-bound inactive state [16], we and others have pro-
posed that GMS proteins protect cellular endomem-
branes from GKS action [20, 21], essentially according
to the “missing X” model of Martens [15]. Following this
idea, herein, we have concentrated on the striking fact
that there are three different GMS proteins, each
localized to specific organellar compartments in the
IFN-γ-stimulated cell. Furthermore, all three GMS pro-
teins are needed to prevent spontaneous activation of
GKS proteins [16]. Since the cellular defects in Irgm1-
deficient mice are dependent on IFN-γ signaling, we
hypothesize here that the absence of specific GMS pro-
teins should result in accumulation and activation of
IFN-γ-induced GKS proteins on specific cytoplasmic or-
ganelles, and this might result in distinct targeted cellu-
lar pathologies characteristic of each GMS deficiency.
Specifically, loss of Irgm1 could result in activation of
GKS proteins on lysosomes, while loss of Irgm3 could
result in activation of GKS proteins on ER membranes.
In the first description of the Irgm1 deficient mouse
[4], the authors speculated that the protein might be in-
volved in transport of materials to PVMs, and included a
possible role in acidification of lysosomes. Subsequently,
a defect in acidification was found in lysosomes from
mycobacterial phagosomes in macrophages from Irgm1-
deficient mice [28], and more recently evidence has been
adduced for autophagic flux impairment in IFN-γ-
induced Irgm1-deficient cells [48], consistent with a le-
sion associated with lysosomal function. In cells deficient
for Irgm1 alone, we now show that IFN-γ-induced GKS
proteins accumulate in the active state specifically on
lysosomal membranes, while in Irgm3−/− cells GKS pro-
teins accumulate and activate specifically on ER mem-
branes. As recently shown [21] and here confirmed, in
Irgm1/Irgm3−/− cells GKS proteins are, surprisingly, lo-
calized on lipid droplets, but not on lysosomes or ER as
expected from the Irgm1 or Irgm3 deficiencies individu-
ally. In Irgm1-deficient cells we show that GKS-coated
lysosomes have an acidification defect and their ability
to process autophagosomes and other substrates is im-
paired. Thus, autophagic flux, which is essential for
lymphocyte survival [49, 50], is partially blocked and
may well be responsible for the lymphomyeloid defects
Fig. 1 Oligomerization model of Irga6 proposed by Martens in 2004 [15]. Irga6 (labelled according to the old nomenclature as IIGP1) shuttles
between endoplasmic reticulum membranes and cytosol. Nucleotide-dependent oligomerization of Irga6 is prevented at the membrane by a yet
unknown factor (X). X is missing from the Toxoplasma gondii parasitophorous vacuole allowing Irga6 oligomerization at the vacuole
Maric-Biresev et al. BMC Biology  (2016) 14:33 Page 3 of 20
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and lymphopenia in Irgm1−/− mice. In contrast, in IFN-
γ-induced cells from Irgm3−/− and Irgm1/Irgm3−/− mice,
which have no generalized immunodeficiency, GKS pro-
teins do not accumulate on lysosomes and autophagic
flux is normal. In view of the documented sensitivity of
lymphomyeloid cells to autophagic injury [49, 50], we
propose that the autophagic pathology induced by IFN-γ
in Irgm1-deficient cells is responsible for the generalized
immunodeficiency of the Irgm1 mouse. The shift of
activated GKS proteins from lysosomes to lipid droplets
in the Irgm1/Irgm3 double-deficient mouse is thus
responsible for the unexpected rescue of Irgm1
immunodeficiency.
Results
Irga6 co-localizes with the lysosomal compartment in
Irgm1-deficient cells
Irgm1 is the only GMS protein known to localize to the
lysosomal compartment [25], while Irgm3 is the only
GMS protein known to localize to the ER [31]. There-
fore, if GMS proteins protect the endocellular mem-
branes against GKS protein activation, Irgm1 deficiency
should result in accumulation of activated GKS proteins
on lysosomal membranes, while Irgm3 deficiency should
result in accumulation of activated GKS proteins, such
as Irga6, on ER membranes.
To test this idea, immortalized WT mouse embryonic
fibroblasts (MEFs), Irgm1−/− MEFs, Irgm3−/− MEFs, and
Irgm1/Irgm3−/− MEFs, all on a C57BL/6 background,
were induced with IFN-γ for 24 hours and stained for
Irga6 and for the late endosome/lysosome marker
lysosomal-associated membrane protein 1 (LAMP1). In
IFN-γ-induced WT MEFs, Irga6 retained the typical
smooth non-aggregated pattern associated with the in-
active state [17]. Irga6 formed aggregates in all GMS
mutant cells, but clear ring-like forms co-localized with
LAMP1 only in Irgm1−/− cells (Fig. 2a, b). However, in
Irgm1/Irgm3−/− cells, in which both lysosomes and ER
should lack GMS proteins, Irga6 aggregates do not co-
localize with either of these cytoplasmic structures but
co-localize with lipid droplets, confirming a recent re-
port [21] (Fig. 2a). The Irga6 accumulated at lysosomes
in Irgm1-deficient cells was shown to be in the activated
state by intense staining with the monoclonal antibody
10D7 (Additional file 1: Figure S1), shown previously to
bind preferentially to the active state of Irga6 [33].
To confirm that Irga6 localization to lysosomes is
dependent specifically on Irgm1 deficiency, we have used
another approach previously employed to demonstrate
the regulatory function of GMS proteins [16]. Mouse
3T3 fibroblasts carrying stable transfected inducible con-
structs expressing Irga6 (Gene Switch (gs) 3T3-Irga6)
were induced with mifepristone (MIF) and simultan-
eously transiently transfected with combinations of vec-
tors expressing Irgm1, Irgm2, or Irgm3 (Fig. 2c,
Additional file 2: Figure S2). These cells were not in-
duced with IFN-γ and thus did not express endogenous
IRG proteins, but only the induced Irga6 and the trans-
fected GMS proteins. To distinguish transiently trans-
fected from non-transfected cells, cytosolic pmCherry
was co-transfected with the GMS constructs. Co-
localization of Irga6 and LAMP1 was analyzed in
mCherry-positive cells. In cells transfected with both
Irgm2 and Irgm3, analogous to the GMS situation in
Irgm1−/− cells, more than 70 % of Irga6 accumulations
co-localized with LAMP1 structures (Fig. 2d). In cells
transfected only with Irgm3, more than 35 % of Irga6 ac-
cumulations were also co-localized with LAMP1, while
in cells transfected only with Irgm1 or in non-
transfected MIF-induced cells, less than 10 % Irga6 ac-
cumulations co-localized with LAMP1. As previously
shown [16], when Irgm1, Irgm2, and Irgm3 were all co-
transfected into MIF-induced cells, Irga6 showed the
smooth non-aggregated appearance of the inactive state
(Additional file 2: Figure S2).
To test whether transiently transfected EGFP-tagged
Irga6 localizes to LAMP1 structures in the same manner
as endogenous Irga6, Irgm1−/− MEFs were induced with
(See figure on previous page.)
Fig. 2 In the absence of Irgm1, Irga6 co-localizes with lysosomes. a Wild type (WT), Irgm1−/−, Irgm3−/−, and Irgm1/Irgm3−/− mouse embryonic
fibroblasts (MEFs) were induced with 200 U/mL IFN-γ for 24 hours. Cells were fixed and stained with anti-Irga6 antiserum (165/3) and anti-LAMP1 anti-
body. Representative microscopic images of Irga6 and lysosome co-localization are shown. Arrows point at the Irga6 structures magnified at the end
of each panel in the following array: upper left: Irga6, upper right: LAMP1, lower left: merge, lower right: phase contrast. Scale bars represent 10 μM. b
Quantification of 2a, showing percentage of Irga6 aggregate-like structures co-localizing with LAMP1. Irga6 does not form aggregate-like structures in WT
cells and therefore it was not quantified; 100 cells per sample were quantified and the means of three independent experiments ± standard deviation are
shown. c Gene switch (gs) 3T3 cells stably transfected with inducible Irga6 were stimulated with mifepristone and simultaneously transiently transfected
with pGW1H-Irgm1, pGW1H-Irgm2, and pGW1H-Irgm3 either alone or in combination and incubated for 24 hours. Samples were fixed and stained as in
1a. Representative images of Irga6 and lysosome co-localization are shown. Images of the cells transfected with additional combinations of GMS proteins
are also included (Additional file 2: Figure S2). Arrows point at Irga6 structures magnified at the end of each panel in the following array: upper left: Irga6,
upper right: LAMP1, lower left: overlay, lower right: phase contrast. Scale bars represent 10 μm. d Quantification of 2c and S2, showing percent of Irga6
structures co-localizing with LAMP1; 50 cells per sample were quantified and counts of two independent experiments are shown. e Irgm1−/− MEFs were
induced with 200 U/mL IFN-γ and simultaneously transiently transfected with pEGFP-Irga6-ctag. Upon 24 h cells were fixed and stained for LAMP1. Scale
bars represent 10 μM
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Fig. 3 Other GKS proteins co-localize with lysosomes in Irgm1−/− cells. a Wild type (WT), Irgm1−/−, Irgm3−/−, and Irgm1/Irgm3−/− mouse embryonic
fibroblasts (MEFs) were induced with 200 U/mL IFN-γ for 24 hours. Cells were fixed and stained with anti-Irgb6 antiserum (141/3) and anti-LAMP1 anti-
body. Representative microscopic images of Irgb6 and lysosome co-localization are shown. Arrows point at the Irgb6 structures magnified at the end
of each panel in the following array: upper left: Irgb6, upper right: LAMP1, lower left: merge, lower right: phase contrast. Scale bars
represent 10 μM. b Quantification of 3a, S3A and S3B, showing percent of Irgb6, Irgb10, and Irgd structures co-localizing with LAMP1;
50 cells per sample were quantified and results of two independent experiments are shown. c Irgm1−/− MEFs were induced with 200
U/mL IFN-γ for 24 hours, fixed and stained for Irga6 (10D7), Irgb6 (141/3) and LAMP1; Irgd, Irga6 (10D7) and LAMP1; Irga6 (10D7),
Irgb10 and LAMP1; or Irgb6 (A20), Irgb10 and LAMP1. Representative microscopic images of GKS structures and lysosome co-
localization are shown. Arrows point at the GKS structures which are magnified at the end of each panel in the following array: upper
left: first GKS protein, upper right: second GKS protein, lower left: LAMP1, lower right: merge. Scale bar represents 10 μM
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IFN-γ and simultaneously transfected with the pEGFP-
Irga6 construct. EGFP-Irga6 indeed co-localized with ly-
sosomes like endogenous Irga6 (Fig. 2e), indicating that
EGFP-Irga6 can also be used for co-localization studies.
Taken together with the data in Fig. 2a, these findings
show that Irga6 accumulates on LAMP1-positive organ-
elles when Irgm1 is the only GMS protein absent from
the cell.
Other GKS proteins also localize to lysosomes in Irgm1−/−
cells
To investigate whether other GKS proteins also co-
localize to LAMP1 in the absence of Irgm1, WT MEFs,
Irgm1−/− MEFs, Irgm3−/− MEFs, and Irgm1/Irgm3−/−
MEFs were induced with IFN-γ and stained for the GKS
proteins Irgb6, Irgb10, and Irgd and for LAMP1 (Fig. 3a,
Additional file 3: Figure S3). More than 90 % of all GKS
protein accumulations tested co-localized with LAMP1
in Irgm1−/− cells and less than 5 % did so in Irgm3−/−
and Irgm1/Irgm3−/− cells (Fig. 3b).
Loading of activated IRG proteins onto T. gondii vacu-
oles shows characteristics of cooperativity and hierarchy
in the sense that several GKS proteins tend to load onto
the same vacuoles and do so in a particular temporal
order, in which Irga6 and Irgd can load only onto vacu-
oles already loaded with Irgb6 and/or Irgb10 [19]. We
therefore tested the possibility of hierarchy and coopera-
tivity of IRG loading onto lysosomes. Irgm1−/− MEFs
were induced with IFN-γ and stained for LAMP1 and
for pairs of GKS proteins (Fig. 3c). Analysis of GKS pro-
tein combinations loaded at the lysosomes (Table 1) in-
dicates a strict but distinct hierarchy in which Irga6 and
Irgb10 can localize to the lysosome independently, while
Irgb6 and Irgd can localize only to Irga6- and/or Irgb10-
coated lysosomes. Irga6 and Irgb10 loading onto the ly-
sosomes occur independent of each other. As observed
for T. gondii vacuoles [19], not all LAMP1-positive or-
ganelles were coated with GKS protein accumulations.
In these experiments, Irga6 was detected using 10D7
antibody, again confirming the activated state of Irga6 in
the aggregates and accumulations.
Irga6 co-localizes with endoplasmic reticulum in Irgm3−/−
cells
Since Irgm3 is the only GMS protein identified as local-
izing to the ER [31], we asked whether, in the absence of
Irgm3, Irga6 accumulates on the ER. WT, Irgm1−/−,
Irgm3−/−, and Irgm1/Irgm3
−/− MEFs were induced with
IFN-γ and simultaneously transfected with an ER
marker, pEYFP-calreticulin. The cells were again stained
for activated Irga6 with 10D7 antibody (Fig. 4a). The
Irga6 structures formed in GMS knock-out (KO) cells
consist of activated, GTP-bound Irga6 [16, 33]. More
than 85 % of active Irga6 accumulations co-localized
with calreticulin in Irgm3−/− cells (Fig. 4b). In contrast,
fewer than 5 % of active Irga6 structures co-localized
with calreticulin in Irgm1−/− cells. These results strongly
support the idea that the positioning of individual GMS
proteins on specific endomembrane systems determines
the inhibition of activation of GKS effector proteins on
the same membranes.
Irga6 co-localizes with lipid droplets in Irgm1/Irgm3−/−
cells
Most of the activated GKS proteins in Irgm1−/− cells co-
localize with the lysosomes and in Irgm3−/− cells with
the ER. The simple prediction is that both membrane
systems will carry activated GKS proteins in the Irgm1/
Irgm3 double KO. However, although these membranes
should be GMS-free in Irgm1/Irgm3−/− cells, neither is
coated with GKS proteins (Figs. 2a and 4a). We there-
fore sought to confirm a recent report showing that in
Irgm1/Irgm3−/− cells activated GKS proteins co-localize
with Bodipy-stained lipid droplets, to which both Irgm1
and Irgm3 both normally localize [21].
IFN-γ-induced Irgm1−/−, Irgm3−/−, and Irgm1/Irgm3−/−
MEFs were stained with anti-Irga6 antibody and with
the neutral lipid dye LD540 (Fig. 5a). In accordance with
Table 1 Cooperativity and hierarchy of IRG loading to lysosomesa






Irga6 + Irgb6 1 1090 713 305 4 68 <0.0001 Cooperative
2 1477 768 536 14 159 <0.0001
Irga6 + Irgd 1 1692 880 503 18 291 <0.0001 Cooperative
2 1232 702 299 8 223 <0.0001
Irga6 + Irgb10 1 899 437 257 123 82 0.7995 Independent
2 1337 570 459 184 124 0.5973
Irgb10 + Irgb6 1 1060 866 144 2 48 <0.0001 Cooperative
aLysosomes carrying or not carrying IRG proteins were identified microscopically by co-staining with antibodies against LAMP1 and different pairs of
IRG proteins
bP values were calculated in a χ2 analysis with 3 d.f. of the four categories of lysosome, based on expectation of random assortment of the two IRG proteins
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the previous report [21], about 70 % of Irga6 structures
co-localized with lipid droplets in Irgm1/Irgm3−/− MEFs,
less than 20 % did so in Irgm3−/− cells, and almost none
did so in Irgm1−/− cells (Fig. 5b).
It has not been reported where activated Irga6 local-
izes in MIF-induced gs3T3 Irga6 cells in the absence of
all GMS proteins. We tested the possibility that activated
Irga6 accumulates on lipid droplets in the current condi-
tions. MIF-induced gs3T3 Irga6 cells were stained with
anti-Irga6 antibody and with LD540 dye (Fig. 5c). Less
than 5 % of Irga6 aggregates were co-localized with the
lipid droplets, indicating that this is not the primary
GKS-target compartment in gs3T3 cells (Fig. 5d). We
could also show that Irga6 does not co-localize with
mitochondria in gs3T3 cells (Additional file 4: Figure
S4). The compartment in which Irga6 activates in the
absence of all GMS proteins remains unidentified.
Irga6 does not co-localize with the Golgi in the absence
of GMS proteins
The Golgi complex in IFN-γ-induced WT cells is nor-
mally coated with both Irgm1 and Irgm2. Because of the
presence of Irgm2, the Golgi therefore should not be
GMS-free in Irgm1−/−, Irgm3−/−, or Irgm1/Irgm3−/− cells.
To test whether GKS proteins accumulate at the Golgi
in GMS KO cells, these cells were induced with IFN-γ
and stained for the Golgi marker GM130 and for Irga6.
As anticipated, in all GMS KO cells, less than 3 % of
Irga6 co-localized with Golgi (Additional file 5: Figure
S5). However, to analyze GKS co-localization with the
Golgi in cells with other GMS protein combinations,
gs3T3 cells were induced with MIF to express Irga6,
transfected with combinations of different GMS proteins
and stained for the Golgi marker GM130 and Irga6. In
none of the samples, even in those where the Golgi
should be GMS-free, was there co-localization of Irga6
with GM130 (Additional file 6: Figure S6). Thus, protec-
tion of Golgi membranes from ectopic activation of GKS
proteins cannot apparently be accounted for by the pres-
ence of GMS proteins.
Irgm1−/− MEFs show autophagic flux impairment and
defective lysosomal degradation
A variety of infections that increase IFN-γ levels in mice
and induce IRG protein expression cause striking
leukopenia and death in Irgm1−/− mice but not in Irgm1/
Irgm3−/− mice [35]. Since GKS proteins re-localize to ly-
sosomes in Irgm1−/− MEFs but not in Irgm1/Irgm3−/−
MEFs, we investigated whether GKS protein activation
on lysosomes can cause lysosomal dysfunction. This
could contribute to the systemic Irgm1−/− mouse
phenotype.
Autophagosomes are degraded by fusion with lyso-
somes, resulting in a flux of autophagic material through
this compartment [51]. It has been previously reported
that levels of p62 protein, which directs ubiquitinated
substrates for autophagic degradation, are increased in
IFN-γ-induced Irgm1−/− cells as a result of autophagic
flux impairment [48]. Moreover, an increased number of
microtubule associated protein 1 light chain 3 (LC3)
punctae has been shown in Irgm1−/− HSCs, also indicat-
ing autophagic changes [47]. To better understand these
autophagic flux alterations, processing of LC3, seen as
LC3-I to LC3-II turnover, was monitored by western
Fig. 4 Irga6 co-localizes with the endoplasmic reticulum in Irgm3−/− cells. a Irgm1−/−, Irgm3−/−, and Irgm1/Irgm3−/− mouse embryonic fibroblasts
(MEFs) were induced with 200 U/mL IFN-γ and transfected with pEYFP-calreticulin for 24 hours. Cells were fixed and stained with anti-Irga6 anti-
body (10D7). Representative microscopic images of Irga6 and calreticulin co-localization are shown. Arrows point at the Irga6 structures magnified
at the end of each panel in the following array: upper left: Irga6, upper right: calreticulin, lower left: merge, lower right: phase contrast. Scale bars
represent 10 μM. b Quantification of 4a, showing percent of Irga6 structures co-localizing with calreticulin; 50 cells per sample were quantified
and the means of three independent experiments ± standard deviation are shown
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blot analysis (Fig. 6a). WT, Irgm1−/−, Irgm3−/−, and
Irgm1/Irgm3−/− MEFs were treated with IFN-γ, with the
autophagy inducer rapamycin (RAP), or left untreated.
The intensity of the LC3-II band was noticeably in-
creased only in IFN-γ-treated Irgm1−/− MEFs in com-
parison to the other samples (Fig. 6b), a result consistent
with the behavior of p62 in an earlier study [48]. How-
ever, the intensity of LC3-I was not reduced in these
cells. Increase in LC3-II could be an outcome of two
scenarios: firstly, autophagy induction might be en-
hanced in IFN-γ-treated Irgm1−/− cells; secondly, au-
tophagic flux might be impaired in the lysosomes of
these cells so that LC3-II cannot be further processed
and degraded. The fact that the LC3-I level was not re-
duced in these cells supports the second scenario. We
therefore investigated LC3 distribution in Irgm1−/− cells
in more detail. WT MEFs and Irgm1−/− MEFs were
treated with IFN-γ and/or RAP or left untreated, and
further stained with LC3 antibody (Additional file 7:
Figure S7). As expected, LC3 formed a large number of
puncta-like structures in RAP-treated cells and only few
small punctae in non-treated cells. However, a large
number of LC3 punctae could be observed in IFN-γ-
induced Irgm1−/− MEFs, even though they were not
RAP induced, indicating an increased number of
autophagosomes.
We next analyzed the co-localization of LC3 punctae
with LAMP1-positive structures in these cells. In all WT
MEFs and in untreated or RAP-treated Irgm1−/− MEFs,
very few LC3-positive structures co-localizing with lyso-
somes were observed, even when a large number of LC3
punctae was present in RAP-treated cells. However, in
Fig. 5 Irga6 co-localizes with lipid droplets in Irgm1/Irgm3−/− cells. a Irgm1−/−, Irgm3−/−, and Irgm1/Irgm3−/− mouse embryonic fibroblasts (MEFs) were
induced with 200 U/mL IFN-γ for 24 hours. Cells were fixed and stained with anti-Irga6 antibody (10D7) and neutral lipid dye LD540. Representative
microscopic images of Irga6 and lipid droplet co-localization are shown. Arrows point at the Irga6 structures magnified at the end of each panel in the
following array: upper left: Irga6, upper right: LD540, lower left: phase contrast, lower right: merge. Scale bars represent 10 μM. b Quantification of 5a,
showing percent of Irga6 structures co-localizing with LD540 (liquid droplets); 50 cells per sample were quantified and results of two independent
experiments are shown. c gs3T3 cells stably transfected with inducible Irga6 were stimulated with mifepristone for 24 hours. Samples were fixed and
stained as in 5a. Representative microscopic images of Irga6 and LD540 co-localization are shown. Arrows point at the Irga6 structures magnified at
the end of each panel in the following array: upper left: Irga6, upper right: LD540, lower left: phase contrast, lower right: merge. d Quantification of 5c,
showing percent of Irga6 structures co-localizing with lipid droplets; 50 cells per sample were quantified and results of two independent experiments
are shown
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Fig. 6 IFN-γ-induced Irgm1−/− mouse embryonic fibroblasts (MEFs) show autophagic flux impairment. a WT, Irgm1−/−, Irgm3−/−, and Irgm1/Irgm3
−/− MEFs were induced with 200 U/mL IFN-γ for 24 hours, 40 μg/mL rapamycin (RAP) for 2 hours or left untreated. Samples were lysed and equal
sample amounts were analyzed by SDS-PAGE/western blot. Western blots were probed with anti-LC3 and anti-actin antibody. b Quantification of
6a, representing ratios of LC3-II and actin band intensities for each sample. Results of four independent experiments are shown. Asterisks mark
samples that were not included in the specific experiment. c Wild type (WT) and Irgm1−/− MEFs were induced with 200 U/mL IFN-γ for 24 hours,
40 μg/mL RAP for 2 hours, or left untreated. Cells were fixed and stained for LC3 and LAMP1. Representative microscopic images of LC3 and
LAMP1 co-localization are shown. Arrows point at the LC3 structures magnified at the end of each panel in the following array: upper left: LC3,
upper right: LAMP1, lower left: merge, lower right: phase contrast. Scale bars represent 10 μM. d Quantification of 6c and S7, showing percent of
LC3 structures co-localizing with LAMP1; 50 cells per sample were quantified and the results of two independent experiments are shown. e WT
and Irgm1−/− MEFs were induced with 200 U/mL IFN-γ for 24 hours or left untreated and transfected with EGFP-LC3. Cells were fixed and stained
for LAMP1, Irga6 (165/3), and Irgb10. Irga6 and Irgb10 were detected with the same secondary antibody (Donkey anti-rabbit Alexa555), so they
both appear in the same channel. Representative microscopic images of LC3, LAMP1, and Irga6/Irgb10 co-localization are shown. Arrows point at
the LC3 structures shown in enlargement at the end of each panel in the following array: upper left: LC3, upper right: Irga6 and Irgb10, lower left:
LAMP1, lower right: Merge of Irga6, Irgb10, and LC3. Scale bars represent 10 μM. f Quantification of 6e, showing percent of LC3 structures co-
localizing with LAMP1 and percent of LC3 structures co-localizing with Irga6, Irgb10, and LAMP1; 50 cells per sample were quantified and the
results of two independent experiments are shown
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IFN-γ-induced Irgm1−/− cells, independently of RAP
treatment, 60–80 % of LC3 punctae co-localized with ly-
sosomes (Fig. 6c, d; Additional file 8: Figure S8). This
suggested that autophagosomes cannot be further proc-
essed and degraded after fusion with lysosomes in IFN-
γ-induced Irgm1−/− cells.
We then asked whether the lysosomes that are unable
to process LC3 are the same lysosomes that are coated
with activated GKS proteins. Irgm1−/− MEFs were in-
duced with IFN-γ, transfected with EGFP-LC3, and
stained for LAMP1, Irga6, and Irgb10 (Fig. 6e). As in the
previous experiment, a large percentage of LC3 co-
localized with LAMP1 in IFN-γ-induced Irgm1−/− cells
and a large percentage of these LC3 punctae co-
localizing with LAMP1 were also associated with GKS
proteins Irga6 and Irgb10 (Fig. 6f ). It therefore seems
plausible that the LC3 processing impairment in Irgm1
−/− cells is caused by the accumulation of activated GKS
proteins on the lysosomes. The autophagosomal com-
partments with impaired function in the Irgm1-deficient
cells have clearly fused with lysosomes since they are
LAMP1 positive. In this respect, our results differ sig-
nificantly from Traver et al. [48], who were unable to de-
tect LAMP1 staining associated with the Irga6 positive,
Gbp2 positive aggregates, while our data show that acti-
vated Irga6 in the Irgm1-deficient cells is almost exclu-
sively associated with LAMP1 positive structures.
Since lysosomes of IFN-γ-induced Irgm1−/− cells
were apparently not able to process autophagosomes,
we asked whether the general processing activity of
these lysosomes is impaired. We first analyzed the pH
status of Irga6-coated lysosomes with the pH sensitive
lysosomal dye Lysotracker on live, non-fixed cells.
Irgm1−/− MEFs were transfected with EGFP-Irga6 and
simultaneously induced with IFN-γ (Fig. 7a). EGFP-
Irga6 structures that co-localized with Lysotracker
were quantified (Fig. 7b). Out of 11.7 Irga6 structures
per cell, only 3.1 were Lysotracker-positive. We show
above that EGFP-Irga6 structures co-localize com-
pletely with LAMP1 (Fig. 2e). Therefore, the data
show that the pH of the majority of Irga6-coated
lysosomes in IFN-γ-induced Irgm1−/− cells is raised,
resulting in an impairment of autophagosome
processing.
We also analyzed lysosomal degradation of DQ-BSA
[52]. In this substrate, a fluorescent dye is quenched by
the protein carrier, but revealed when the substrate is
processed in lysosomes. WT, Irgm1−/−, Irgm3−/−, and
Irgm1/Irgm3−/− MEFs were treated with IFN-γ, with the
lysosomal acidification inhibitor Bafilomycin A1 (BAF),
or left untreated. Samples were incubated with DQ-BSA.
The numbers of DQ-positive punctae were evaluated
blind on pictures of live cells (Fig. 7c). IFN-γ-induced
Irgm1−/− MEFs had 30–50 % fewer punctae than non-
induced Irgm1−/− MEFs (Fig. 7d). This difference was
not observed in WT, Irgm3−/−, or Irgm1/Irgm3−/− MEFs.
As expected, the number of DQ-punctae in BAF-treated
cells was reduced by more than 80 %. Thus, it seems
that GKS-coated lysosomes are not only impaired in
autophagosomal processing, but also in processing of ex-
ogenous substrates.
GKS proteins probably do not permeabilize lysosomal
membranes in Irgm1−/− cells
After observing that GKS proteins localize to LAMP1
structures in Irgm1−/− cells, we considered the possi-
bility that these GKS proteins might disrupt the lyso-
somal membrane in in the same way that they
mediate disruption of the T. gondii PVM. Hence, the
outcome of GKS accumulation to the lysosomes could
be lysosomal membrane permeabilization (LMP). This
would cause not only breakdown of the pH gradient
but also lysosomal enzyme leakage and presumably
death of the cell [53].
To analyze the possibility of necrotic cell death, WT
and Irgm1−/− MEFs were induced with IFN-γ or left un-
treated. Treatment with the LMP inducer LeuLeuOMe
[54, 55] was used as a positive cell death control. After
24, 48, or 72 hours, live cells were stained with cell-
permeant DNA binding Hoechst dye, which stains the
nuclei of live and dead nuclei, and cell-impermeant pro-
pidium iodide (PI), which stains only the nuclei of dead
cells (Fig. 8a). No difference in cell death between WT
and Irgm1−/− MEFs was observed (Fig. 8b). We repeated
this experiment in WT bone marrow derived macro-
phages (BMDM) and Irgm1−/− BMDMs, which were in-
duced with IFN-γ, lipopolysaccharide, LeuLeuOMe, or
left untreated (Fig. 8c). As previously reported in a simi-
lar analysis [6], no difference in cell death between the
two cell populations was observed.
Taken together, even though it is a characteristic of ac-
tivated Irgm1−/− lymphocytes [35], necrotic cell death
was not observed in IFN-γ-induced Irgm1−/− MEFs and
BMDMs. Moreover, lack of cell death in these samples
largely excludes the possibility of lysosomal membrane
permeabilization.
To further consider the possibility that GKS proteins
cause lysosomal permeabilization in Irgm1−/− cells
without causing massive necrosis, we analyzed the re-
lease of the lysosomal enzyme cathepsin B into the
cytosol (Additional file 9: Figure S9) compared with
the release induced by a just sub-lethal concentration
of the pronecrotic peptide LeuLeuOMe.
WT MEFs and Irgm1−/− MEFs were left un-treated, in-
duced with IFN-γ, or treated with 3 mM LeuLeuOMe.
Cells were fixed and stained for cathepsin B (Additional
file 9: Figure S9C) and the small, sharply-defined cathep-
sin B punctae indicating intact lysosomes counted
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(Additional file 9: Figure S9D). Both, LeuLeuOMe-
treated WT and LeuLeuOMe-treated Irgm1−/− cells had
fewer cathepsin B punctae than non-treated cells and
also contained localized, larger diffuse stained regions
presumably indicating local lysosomal damage and ca-
thepsin B release. However, the number of sharply-
defined cathepsin B punctae in IFN-γ-induced Irgm1−/−
MEFs was very similar to untreated Irgm1−/− MEFs as
well as treated and untreated WT MEFs, and the
characteristic diffusely stained regions found in the
LeuLeuOMe-treated cells were not seen. Taken to-
gether, these data indicate that GKS proteins, which
are localized to lysosomes, do not mediate significant
lysosomal membrane permeabilization in IFN-γ-induced
Irgm1−/− fibroblasts and macrophages.
Discussion
The argument that Irgm1 is an important pathogen re-
sistance molecule in mice has largely relied on the dra-
matic loss of resistance to numerous pathogens resulting
from elimination of Irgm1 by gene targeting. This inter-
pretation has persisted despite the clear demonstration
that Irgm1 deficiency has large systemic effects on the
lymphomyeloid system. Lymphomyeloid collapse is in-
duced by infection in Irgm1-deficient animals [34]
caused, at least in part, by constitutive exhaustion of
HSCs in these animals [45]. Loss of general pathogen re-
sistance is thus most plausibly accounted for by the pro-
found damage to the lymphomyeloid system in Irgm1
deficiency. The critical question is thus not how Irgm1
functions as a pathogen resistance molecule, but rather
Fig. 7 Lysosomal processing is impaired in IFN-γ-induced Irgm1−/− mouse embryonic fibroblasts (MEFs). a Irgm1−/− MEFs were transfected with EGFP-
Irga6 and simultaneously induced with 200 U/mL IFN-γ. After 24 hours, non-fixed cells were incubated with 50 nM Lysotracker for 15 minutes and
pictures of live cells were taken. Representative microscopic images of Irga6 and Lysotracker co-localization are shown. Arrows point at the Irga6
structures magnified at the end of each panel in the following array: upper left: Irga6, upper right: Lysotracker, lower left: merge, lower right: phase
contrast. Scale bars represent 10 μM. b Quantification of 7a showing the number of Irga6 structures co-localizing with Lysotracker. 25 cells per sample
were quantified and the means of three independent experiments ± standard deviation are shown. c Wild type (WT), Irgm1−/−, Irgm3−/−, and Irgm1/
Irgm3−/− MEFs were induced with 200 U/mL IFN-γ for 27 hours, 200 nM μg/mL Bafilomycin A1 for 4 hours, or left untreated. After 24 hours, non-fixed
cells were incubated with 10 μg/mL DQ-BSA, incubated for 3 hours, and images of live cells were taken. Representative microscopic images of DQ-BSA
staining are shown. Scale bars represent 10 μM. d Quantification of Fig. 7c showing the average numbers of DQ-positive structures per cells; 20 cells
per sample were evaluated and results of three independent experiments ± standard deviation are shown. Differences were tested for statistical
significance using the Mann-Whitney test (NS P > 0.03)
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why its absence causes this dramatic phenotype. The
issue was further complicated when Taylor and col-
leagues showed that loss of a second regulatory member
of the IRG system, Irgm3, almost completely rescued the
Irgm1 deficiency phenotype, both in terms of lympho-
myeloid collapse and pathogen resistance [6]. Absence
of Irgm1, per se, could therefore not be responsible for
the problem. However, the Irgm1/Irgm3 double-
deficient animals were not completely normal: despite a
normal lymphomyeloid system, they remained fully sus-
ceptible to Toxoplasma gondii [6] and their cells cannot
inhibit E. cuniculi replication after IFN-γ treatment [14].
Indeed, Irgm1 and Irgm3 are functional regulators of the
IRG resistance system [16] and since their absence leaves
animals vulnerable to those few pathogens that are con-
trolled by the IRG resistance system, they may legitim-
ately be described as resistance factors. However, the
catastrophic phenotype of the Irgm1-alone-deficient
mouse is clearly something different, and it was the
motive of this study to point to the causal chain leading
to this dramatic outcome.
It has been proposed that effector proteins of the IRG
system (GKS proteins) target pathogen-containing vacu-
oles in IFN-γ-induced cells through the absence on the
vacuolar membranes of the GMS regulatory proteins of
the IRG system [14–16, 20–22]. In this model, GKS
Fig. 8 Irgm1−/− mouse embryonic fibroblasts (MEFs) and bone marrow derived macrophages (BMDMs) do not die upon IFN-γ induction. a Wild type (WT)
and Irgm1−/− MEFs were induced with 200 U/mL IFN-γ or treated with 10 mM LeuLeuOMe for 24, 48, and 72 hours, or left untreated. Cells were stained
with nuclear dyes Hoechst (all cells) and propidium iodide (PI; dead cells only). Representative microscopic images of Hoechst- and PI-stained WT cells are
shown. Scale bar represents 100 μM. b Quantification of 8a showing the percentage of PI-positive MEFs. Dye stained nuclei were quantified with the
Volocity software; 10 pictures (5000–10000 cells) per sample were quantified and the means of three independent experiments ± standard deviation are
shown. c WT and Irgm1−/− BMDM cells were induced with 200 U/mL IFN-γ, 500 ng/mL lipopolysaccharide, 5 mM LeuLeuOMe for 24, 48, and 72 hours, or
left untreated. The experiment was performed as in 8a, b; 10 pictures (5000–10000 cells) per sample were quantified and the means of three independent
experiments ± standard deviation are shown
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proteins would indeed tend to activate on endomem-
brane systems, but would normally be inhibited by GMS
proteins localized to these compartments. This would
prevent potential damage caused by off-target activation
of the GKS proteins on self-membranes and leave the
PVM of the pathogen, as the only GMS-free membrane
in the cell, thus exposed as a target for the effector GKS
proteins. Since different GMS proteins localize to differ-
ent endocellular membranes, absence of a specific GMS
protein would leave a specific endocellular membrane
unprotected and vulnerable to off-target activation of
GKS proteins.
In this study, we have investigated the possibility pro-
posed in our earlier publications [16, 20] that the con-
trasting phenotypes of Irgm1, Irgm3, and the Irgm1/
Irgm3 double deficient mice might be caused by off-
target activation of the GKS proteins at different cellular
endomembranes. We have shown that the localization of
activated GKS proteins to specific compartments is in-
deed dependent on the absence of specific GMS proteins
(Fig. 9). In IFN-γ induces cells in the absence of Irgm1,
activated GKS proteins accumulate at the lysosomes
(Fig. 2a, b), to which Irgm1 normally localizes, while in
the absence of Irgm3, activated GKS proteins accumu-
late at the ER (Fig. 4), to which Irgm3 normally localizes.
In Irgm1/Irgm3−/− cells, in which lysosomes, ER, and
lipid droplets are all GMS-free, GKS proteins activate
exclusively at lipid droplets. Thus, the activation of GKS
proteins on specific endomembrane systems is deter-
mined by the absence of specific GMS proteins (Fig. 5)
[21]. However, the targeting specificity rules are evi-
dently complex. Firstly, when single membrane systems,
e.g., lysosomes alone or ER alone, are GMS-free, GKS
activation occurs only on the GMS-free membranes.
However, when multiple membrane systems are GMS-
free, GKS activation occurs selectively on one set of
GMS-free membranes and not on another. Thus, GKS
proteins may show different preferences for different
endocellular membranes when given a choice, perhaps
on the basis of their lipid composition. To be clear, in
the case of Irgm1/Irgm3−/−, we do not argue that Irgm3
normally interacts directly with Irgm1, or is in any sense
a regulator of the localization of Irgm1, only that the
additional absence of Irgm3 releases further compart-
ments for access by GKS proteins. Secondly, in gs3T3
cells expressing Irga6 under an inducible promoter, but
not transfected with GMS proteins, all endocellular
membranes must be essentially GMS-free (Fig. 2c, d). If
GKS proteins load randomly onto any GMS-free mem-
brane, activated Irga6 should be found on lysosomes,
ER, Golgi, and lipid droplets, but this is not the case. In-
stead, activated Irga6 localizes to a still unidentified
punctate compartment which may, indeed, consist of
freely cytosolic aggregates (Figs. 2d, 5d, and Additional
file 6: Figure S6). Thirdly, when these gs3T3 Irga6 cells
are transfected with Irgm3 only, about 35 % of Irga6 ag-
gregates accumulate at the lysosomes. The Golgi com-
plex, which is normally coated with Irgm1 and Irgm2, is
also GMS-free in these cells. Irga6 would therefore also
be expected to accumulate at Golgi membranes, but this
does not happen. Indeed, the Golgi complex seems to be
immune to GKS activation independently of GMS load-
ing. Finally, none of the endocellular GMS proteins lo-
calizes to the plasma membrane, but this structure is
never coated with GKS proteins, even in WT cells. The
basis for this protection is not known [14]. However,
whatever the critical properties of the plasma membrane
are, they must change rapidly during pathogen entry be-
cause the new pathogen-containing vacuolar membrane
immediately becomes vulnerable to attack by GKS pro-
teins [19]. In summary, the activation of GKS proteins
occurs only on GMS-free membranes, but not necessar-
ily on all. Furthermore, although the location of acti-
vated GKS proteins depends upon which membranes are
GMS-free, the rules of selectivity between potential tar-
get membranes remain unclear.
The consequences of GKS accumulation at different
endocellular membranes are also not completely under-
stood. Alteration of autophagic flux in the absence of
Irgm1 in activated cells has already been proposed in
different models [35, 47, 48]. Our novel claim is that this
is due to the selective accumulation of activated GKS
proteins on lysosomes due to the absence of Irgm1.
Here, we show that the pH of GKS-coated lysosomes in
cultivated Irgm1-deficient fibroblasts is increased and
that these lysosomes cannot process autophagosomes,
causing reduction in autophagic flux (Figs. 6 and 7). Ly-
sosomes free of GKS accumulations in the same cells do
not show an acidification defect. The lysosomes of IFN-
γ-induced Irgm1-deficient cells also cannot process an
exogenous substrate efficiently (Fig. 7).
Lymphocytes, which need to divide rapidly upon infec-
tion, are particularly challenged by autophagic flux arrest
and lysosomal function failure [49, 50], and this may
contribute to the fatal IFN-γ-induced lymphopenia in
Irgm1−/− mice. HSCs, which express IRG proteins in the
absence of infection [56, 57], may be similarly vulnerable
to this lesion in the Irgm1-deficient mouse [45, 47]. An
increased number of microtubule associated protein 1
light chain 3 (LC3) punctae has been shown in Irgm1−/−
HSCs, indicating an autophagic anomaly [47] and fully
consistent with evidence for constitutive expression of
IRG proteins in this compartment. The consequences of
GKS accumulation at the ER in Irgm3−/− cells are not
clear. It has been suggested that Irgm3 deficiency is as-
sociated with enlargement and swelling of this compart-
ment [16, 58], but these mice do not become
lymphopenic after infections that kill Irgm1−/− mice. We
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must conclude that these ER anomalies do not affect the
function of the lymphomyeloid system to the same ex-
tent as they damage the lysosomal system. It has been
proposed that GKS proteins at the lipid droplets in
Irgm1/Irgm3−/− cells help the degradation of this com-
partment via autophagy [21]. These results require fur-
ther investigation, but it is clear that GKS proteins in
these cells are not at the lysosomes and that lysosomal
and autophagic functions are not impaired. According to
our model, this accounts for the fact that Irgm1/Irgm3−/−
mice do not show lymphopenia and do not die from the
multitude of infections that kill Irgm1−/− mice.
As we show, several members of the GKS subfamily
load cooperatively on to lysosomes in Irgm1-deficient
Fig. 9 Model for the cytopathic effects of dysregulated GKS proteins. a Regulatory immunity-related GTPase (IRG) GMS proteins localize to distinct cellular
endomembranes including the endoplasmic reticulum (ER), Golgi, lipid droplets, and lysosomes and maintain effector IRG GKS proteins, which diffuse
transiently onto these compartments, in an inactive GDP-bound state. b When T. gondii enters the host cell, GKS proteins diffuse onto this new
membrane-bound compartment and activate at the parasitophorous vacuole membranes (PVM) because of the absence of GMS proteins. Activated GKS
proteins form GTP-dependent oligomers and disrupt the membrane. c In Irgm1-deficient cells, lysosomal membranes lack any GMS proteins on the
lysosomal membrane, allowing GKS proteins to activate and accumulate forming GTP-bound oligomers. Acidification of these lysosomes is impaired and
with it lysosomal processing is not functional. These lysosomes cannot properly process autophagosomes after lysosome/autophagosome fusion. Hence,
autophagic flux of IFN-γ-induced Irgm1−/− cells is impaired. d In T. gondii-infected Irgm1−/− cells, GKS proteins are accumulated at the lysosomes and
therefore cannot properly accumulate and activate at the PVM. Disruption of the PVM does not happen and T. gondii can further proliferate. e In Irgm3-
deficient cells it is the ER cisternae that are not protected by GMS proteins. Activated GKS proteins accumulate in local aggregates on the ER, possibly
causing local ER deformation, but without such severe consequences for the cell as lysosomal impairment in Irgm1−/− cells. f In T. gondii-infected Irgm3−/−
cells, GKS proteins are accumulated at the ER and therefore cannot properly accumulate and activate at the PVM. Disruption of the PVM does not happen
and T. gondii can proliferate. g In Irgm1/Irgm3−/− cells, lysosomes, ER, and lipid droplets are GMS-free. For unknown reasons, activated GMS proteins
accumulate only at the lipid droplets and not at the other GMS-free compartments. h Upon T. gondii infection of Irgm1/Irgm3−/− cells, GKS proteins
activated at the lipid droplets cannot properly load to the PVM and inhibit T. gondii proliferation
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cells, just as several GKS members load on to T. gondii,
C. trachomatis, and E. cuniculi vacuoles. It is curious
that the priority rules for loading of different GKS pro-
teins differ between T. gondii vacuoles and Irgm1−/−-de-
ficient lysosomes. In no case is it known whether the
consequent damage is due to some form of coordinated
attack, whether the injury is additive, or whether certain
specific GKS members are primarily responsible. In the
present case, we consider it unlikely that the damage to
the lysosomal pH gradient in fibroblasts and macro-
phages is due to frank disruption of the lysosomal mem-
brane. The effect is not lethal while disruption of the
lysosomal membrane would normally initiate necrotic
death. In addition, there is no quantitative loss of
cathepsin-containing organelles or evidence for release
of cathepsins into the cytosol (Fig. 8). Recently, several
studies have reported different aspects of the loading of
guanylate binding proteins onto T. gondii PVMs, C. tra-
chomatis inclusions, and IRG aggregate-like structures
[21, 48, 59–62]. Guanylate binding proteins appear to
load on to a subset of vacuoles that carry IRG proteins.
A role in attracting the autophagic apparatus via ubiqui-
tination has been proposed.
Whatever the basis for the damage to the pH gradient,
the consequences of GKS protein off-target activation
on endogenous organelles can evidently be severe and
may indeed represent a risk and, therefore, a cost for
possession of the IRG system. The spectrum of patho-
gens that are restricted by IRG proteins appears to be re-
markably narrow [14]. Perhaps the loss of the IRG
system in higher primates and certain other animal
groups [2, 63, 64] is the response to a balance between
the cost of carrying an immune resistance mechanism
that can become dangerous and difficult to control,
against the scale of threat posed by the limited pathogen
classes that the mechanism defends against. Indeed,
humans have what appears to be efficient resistance
against most T. gondii strains despite their loss of the
IRG system [2]. How humans distinguish between PVMs
and endomembranes remains unknown.
Conclusions
To summarize, the three members of the GMS subfam-
ily of IRG resistance proteins in mice act as negative reg-
ulators, essentially guanine dissociation inhibitors, of the
GKS effector subfamily. Their role is to prevent the GKS
proteins from activating on endogenous organelles,
while enabling them to accumulate on parasite-
containing vacuoles, which are GMS deficient. Each of
the three GMS proteins localizes to a different specific
subset of intracellular organelles in the interferon-
induced cell. The presence of GMS proteins thus enables
GKS proteins to distinguish organellar “self” cellular
membranes from the membranes of the pathogen
vacuoles. The high susceptibility of Irgm1−/− mice to
multiple infections is caused by off-target GKS protein
activation on lysosomal membranes, collapse of lyso-
somal pH gradient, and consequent failure of autopha-
gosomal processing, a lesion to which members of the
hematolymphoid cell lineage are particularly susceptible.
Our experiments use the history of these phenomena to
show a path of cause and effect between loss of Irgm1
and susceptibility to infection that is far more complex
than the original, and still much cited view, that disease
susceptibility of Irgm1-deficient animals shows that
Irgm1 is an important general disease resistance factor.
Methods
Ethical statement
All animal experiments were conducted under the regu-
lations and protocols for animal experimentation ac-
cording to the German “Tierschutzgesetz” (Animal
Experimentation Law). The local government author-
ities, Landesamt fuer Natur- und Umweltschutz Nordr-
hein Westfalen, and its ethics committee approved the
work (LANUV Permit No. 84–02.05.40.14.004).
Cell culture
Immortalized WT C57BL/6 MEFs, Irgm1−/− MEFs,
Irgm3−/− MEFs, and Irgm1/Irgm3−/− MEFs were pre-
pared as previously described [14]. Cells were cultured
in DMEM, high glucose (Life Technologies, Carlsbad,
CA) supplemented with 10 % FCS (Biochrom, Berlin,
Germany), 2 mM glutamine, 1 mM sodium pyruvate, 1×
MEM non-essential amino acids, 100 U/mL penicillin,
and 100 mg/mL Streptomycin (all Life Technologies).
gs3T3 Irga6 cells were prepared as previously de-
scribed [16] and cultured in the above described
medium with addition of 200 μg/mL Zeocin (Invivogen,
San Diego, CA) and 50 μg/mL Hygromycin (Invivogen).
Irga6 expression was induced with 1 nM mifepristone
(Life Technologies).
Primary BMDMs were isolated from tibia and femurs
of 4- to 5-week-old C57BL/6 mice and Irgm1−/− mice as
previously described [46], and cultured in RPMI 1640
(Life Technologies) supplemented with 20 % FCS,
30 % L 929 cell conditioned medium, 2 mM glutamine,
1 mM sodium pyruvate, 1× MEM non-essential amino
acids, 100 U/mL penicillin, and 100 mg/mL strepto-
mycin (all Life Technologies).
Expression constructs and transfection
The following expression constructs were used: pGW1H-
Irgm1 [19], pGW1H-Irgm2 [19], pGW1H-Irgm3 [19],
pmCherry-N3 [7], pEGFP-Irga6-ctag1 [7], and N-tagged
pEYFP-calreticulin (kindly provided by Dr. Astrid Schauss,
CECAD Imaging Facility), pEGFP-LC3 [8].
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Transient transfection was conducted with 1 μg DNA
per 300,000 cells seeded using 3 μL of X-tremeGENE 9
transfection reagent (Roche, Mannheim, Germany)
according to the manufacturer’s instructions.
Immunological reagents and dyes
The following immunoreagents were used: rabbit anti-
Irga6 antiserum 165/3 [17], mouse anti-Irga6 monoclonal
antibodies (mAb) 10E7 and 10D7 [33], rabbit anti-Irgb6
antiserum 141/3 [65], antibody A20 (Santa Cruz Biotech-
nology, TX, USA), rabbit anti-Irgd antiserum 81/3 [65],
anti-Irgb10 antiserum 940/6 [19], rat anti-LAMP1 mono-
clonal antibody 1D4B (Abcam, Cambridge, United King-
dom), anti-GM130 antibody (BD Biosciences, NJ, USA),
rabbit anti-LC3B antiserum L7543 (Sigma-Aldrich, St.
Louis, MO, USA), rabbit anti-Tom20 antiserum (Santa
Cruz Biotechnology), mouse anti-β-Actin monoclonal
antibody (Sigma-Aldrich), and mouse anti-cathepsin B
antibody (R&D systems, MN, USA). The following sec-
ondary antibodies were used: Alexa Fluor 488/555/647-la-
beled donkey anti-mouse/donkey anti-rabbit/donkey anti-
rat antibody (all Life Technologies), HRP-conjugated goat
anti-mouse antibody and HRP-conjugated donkey anti-
rabbit antibody (both Sigma-Aldrich). Nuclear staining
was performed with 0.5 mg/mL DAPI (Life Technologies),
1 μg/mL PI (Sigma-Aldrich), or 1 μg/mL Hoechst 33342
(Sigma-Aldrich); 50 nM Lysotracker (Life Technologies)
was used for lysosome staining; 0.1 μg/mL LD540 neutral
lipid dye (kindly provided by Christoph Thiele, LIMES,
Bonn) was used for the staining of lipid droplets as previ-
ously described [66].
Immunofluorescence microscopy
Immunofluorescent staining was performed on
paraformaldehyde-fixed cells as described earlier [15].
Images were taken with Zeiss Axioplan II fluorescence
microscope equipped with an AxioCam MRm camera
(Zeiss, Jena, Germany) and processed with Axiovision
4.6 software (Zeiss). Co-localization analysis was per-
formed by visual inspection of coded slides.
Live cell imaging was performed in μ-Slide I chambers
(Ibidi, Martinsried, Germany). Approximately 60,000
cells were seeded in each chamber. After 24 hours, cells
were transfected with 0.5 μg DNA and 1.5 μL X-
tremeGENE 9 and incubated for 24 hours. Imaging was
performed using Axiovert 200 M microscope with an
AxioCam MRM camera (Zeiss) fitted with a wrap-
around temperature-controlled chamber.
SDS-PAGE and Western Blot
Approximately 100,000 MEFs/well were seeded in 12-
well cell culture plates. Samples were induced with 200
U/mL IFN-γ (PeproTech, Rocky Hill, NJ) for 24 hours,
with 40 μg/ml RAP (Sigma-Aldrich) for 2 hours, or left
untreated. Samples were lysed in 80 μL of modified
RIPA buffer (0.1 % NP-40 and 1 % SDS) by 5 minutes of
shaking and 5 minutes of 95 °C incubation. The
amounts of protein were quantified with BCA assay
(Pierce, Rockford, IL, USA) and 20 μg of samples were
subjected to 10 % SDS-PAGE and western blot analysis.
Membranes were blocked in 5 % non-fat dry milk in
TBST buffer and probed for the proteins of interest with
the indicated primary and secondary antibodies. The in-
tensity of the bands was quantified by Quantity One
software (Biorad, Hercules, CA, USA).
Cell death assay
Approximately 200,000 immortalized MEFs or 300,000
BMDMs were seeded on a 6-cm cell culture dish in
2 mL of medium. Samples were induced with 200 U/mL
IFN-γ, 10 mM LeuLeuOMe (Sigma-Aldrich), 500 ng/mL
lipopolysaccharide (Sigma-Aldrich), or left untreated for
24, 48, or 72 hours. Before analysis, 500 μL of medium
containing 2.5 μg/mL PI (Sigma-Aldrich) and 2.5 μg/mL
Hoechst 33342 (Sigma-Aldrich) dye was added directly
to the cells without removing the old medium and incu-
bated for 15 minutes at 37 °C. Ten images of each sam-
ple were taken with the fluorescent Axiovert 200
microscope (Zeiss). The number of Hoechst-positive nu-
clei (blue) and PI-positive (red) punctae was quantified
with the Volocity 6.3 software (Perkin Elmer, Waltham,
MA) in at least 5000 cells per sample.
DQ-BSA assay
Approximately 60,000 WT, Irgm1−/−, Irgm3−/−, and
Irgm1/Irgm3−/− MEFs were seeded in μ-Slide I cham-
bers. After 24 hours, cells were induced with 200 U/mL
IFN-γ or left untreated. After a further 24 hours, cells
were incubated with 10 μg/mL DQ Red BSA (Life tech-
nologies) [52] and in parallel treated with 200 U/mL
IFN-γ or 200 nM Bafilomycin A1 (Sigma-Aldrich) or left
untreated. After 1 hour, samples were twice washed with
PBS and further incubated in medium containing the
corresponding concentration of IFN-γ and Bafilomycin
A1. After 3 hours, pictures of live cells on blinded slides
were taken and the number of DQ-positive punctae was
manually quantified.
Cathepsin B release analysis
To establish a concentration of LeuLeuOMe that can in-
duce LMP without killing the cell, Irgm1−/− MEFs were
treated with different concentrations of this reagent for
24 hours. Cell death was measured with PI/Hoechst
staining assay. The highest tested concentration of Leu-
LeuOMe that did not strongly affect cell survival was
3.75 mM (Additional file 9: Figure S9A). It was further
microscopically tested whether the degree of LMP is
correlated to the number of cathepsin B punctae. To
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induce LMP, Irgm1−/− MEFs were treated with 2, 3, or
4 mM of LeuLeuOMe or left untreated for 24 hours.
Cells were fixed and stained with the anti-cathepsin B
antibody. Pictures of the samples were taken and cathep-
sin B punctae in the cells were manually blind counted
(Additional file 9: Figure S9B). Samples treated with
higher concentrations of LeuLeuOMe had fewer cathep-
sin B punctae per cell, indicating that cathepsin B stain-
ing corresponds to the extent of the LMP in a dose-
dependent manner.
Cooperativity and hierarchy of IRG loading to lysosomes
Irgm1−/− cells were induced with IFN-γ and stained for
LAMP1 and combinations of different IRG proteins
(Fig. 3c). The number of lysosomes that co-localize with
only one or both IRG proteins was quantified in 20–30
cells per sample (~20–80 lysosomes per cell).
Probabilities that the observed values arise from inde-
pendent loading of the two IRG proteins tested were
based on a χ2 comparison of observed values with ex-
pectation from independent loading.
Additional files
Additional file 1: Figure S1. Activated Irga6 co-localizes with the
lysosomes. There is no cross-reactivity between 10D7 and 1D4B antibodies.
Irgm1−/− mouse embryonic fibroblasts were induced with 200 U/mL IFN-γ
for 24 hours. Cells were fixed and stained with mouse antibody 10D7, which
stains the Irga6 in GTP-bound state, and rat antibody 1D4B, which stains
LAMP1 lysosomal marker. The antibodies were visualized with secondary
antibodies Alexa 488 donkey-anti-mouse and Alexa 555 goat-anti-rat. To test
the cross-reactivity, one of the primary or secondary reagents was omitted
in each sample. The images of stained cells were taken. Representative
microscopic images of GTP-bound Irga6 and LAMP1 are shown, with
omitted antibody being annotated. (TIF 14983 kb)
Additional file 2: Figure S2. Irga6 co-localizes with LAMP1 in GMS
transfected cells. Gene Switch 3T3 cells stably transfected with inducible
Irga6 were stimulated with mifepristone and simultaneously transiently
transfected with combinations of pGW1H-Irgm1, pGW1H-Irgm2, and
pGW1H-Irgm3. Upon 24 hours of induction, samples were fixed and
stained as in Fig. 2a. Representative microscopic images of Irga6 and
lysosome co-localization are shown. Arrows point at the Irga6 structures
magnified at the end of each panel in the following array: upper left:
Irga6, upper right: LAMP1, lower left: overlay, lower right: phase contrast.
(TIF 10553 kb)
Additional file 3: Figure S3. Irgd and Irgb10 co-localize with LAMP1 in
Irgm1−/− mouse embryonic fibroblasts (MEFs). Irgm1−/−, Irgm3−/−, and
Irgm1/Irgm3−/− MEFs were induced with 200 U/mL IFN-γ for 24 hours.
Cells were fixed and stained with anti-Irgd antiserum (A) or anti-Irgb10
antiserum (B) and anti-LAMP1 antibody. Representative microscopic
images of Irgd and LAMP1 (A) or Irgb10 and LAMP1 (B) co-localization
are shown. Arrows point at the Irgd or Irgb10 structures magnified at the
end of each panel in the following array: upper left: Irgd or Irgb10, upper
right: LAMP1, lower left: merge, lower right: phase contrast. Scale bars
represent 10 μM. (TIF 7689 kb)
Additional file 4: Figure S4. Irga6 does not co-localize with mitochondria
in GMS-deficient cells. A gs3T3 cells stably transfected with inducible
Irga6 were stimulated with mifepristone for 24 hours. Samples were
fixed and stained with anti-Irga6 antibody (10D7) and anti-Tom20
antibody. Representative microscopic images of Irga6 and Tom20
co-localization are shown. Arrows point at the Irga6 structures
magnified at the end of each panel in the following array: upper left:
Irga6, upper right: Tom20, lower left: merge, lower right: phase
contrast. Scale bars represent 10 μM. B Quantification of S4A,
showing percent of Irga6 structures co-localizing with Tom20.
50 cells per sample were quantified. (TIF 5787 kb)
Additional file 5: Figure S5. Irga6 does not co-localize with the Golgi in
GMS-deficient cells. AWild type, Irgm1−/−, Irgm3−/−, and Irgm1/Irgm3−/− mouse
embryonic fibroblasts were induced with 200 U/mL IFN-γ for 24 hours. Cells
were fixed and stained for Irga6 (165/3) and for Golgi marker GM130.
Representative microscopic images of Irga6 and Golgi co-localization are
shown. Arrows point at the Irga6 structures magnified at the end of each
panel in the following array: upper left: Irga6, upper right: GM130, lower left:
merge. Scale bars represent 10 μM. B Quantification of S5A, showing percent
of Irga6 structures co-localizing with GM130. 50 cells per sample were
quantified. (TIF 8669 kb)
Additional file 6: Figure S6. Irga6 does not co-localize with Golgi in
GMS-transfected cells. A gs3T3 cells stably transfected with inducible
Irga6 were stimulated with mifepristone and simultaneously transiently
transfected with different combinations of pGW1H-Irgm1, pGW1H-Irgm2,
and pGW1H-Irgm3 for 24 hours. Samples were fixed and stained for Irga6
and GM130. Representative microscopic images of Irga6 and Golgi co-
localization are shown. Arrows point at the Irga6 structures magnified at
the end of each panel in the following array: upper left: Irga6, upper right:
Golgi, lower left: merge, lower right: phase contrast. B Quantification of
S6A, showing percent of Irga6 structures co-localizing with GM130. 50
cells per sample were quantified. (TIF 13762 kb)
Additional file 7: Figure S7. Number of autophagosomes is increased
in IFN-γ-induced Irgm1−/− cells. A Wild type and Irgm1−/− mouse
embryonic fibroblasts were induced with 200 U/mL IFN-γ for 24 hours
and/or 40 μg/mL rapamycin for 2 hours, or left untreated. Cells were
fixed and stained for LC3. Representative microscopic images of LC3
punctae and phase contrast are shown. Scale bars represent 10 μm. B
Quantification of S7A, showing average number of LC3 punctae per cell.
50 cells per sample were counted and the results of two independent
experiments are shown. (TIF 7475 kb)
Additional file 8: Figure S8 LC3 co-localizes with LAMP1 in IFN-γ-
induced Irgm1−/− cells. Wild type (WT) and Irgm1−/− mouse embryonic
fibroblasts (MEFs) were induced with 200 U/mL IFN-γ for 24 hours, 40 μg/
mL rapamycin for 2 hours, or left untreated. Cells were fixed and stained
for LC3 and LAMP1. Representative microscopic images of LC3 and
LAMP1 localization in WT and Irgm1−/− MEFs are shown. Arrows point at
the LC3 structures magnified at the end of each panel in the following
array: upper left: LC3, upper right: LAMP1, lower left: merge, lower right:
phase contrast. Scale bars represent 10 μM. (TIF 9874 kb)
Additional file 9: Figure S9. Cathepsin B punctae quantification in
Irgm1−/− mouse embryonic fibroblasts (MEFs). A Irgm1−/− MEFs were
treated with different concentrations of lysosomal permeabilization agent
LeuLeuOMe or left untreated for 24 hours. Cells were stained with
propidium iodide (PI) and Hoechst dye and analyzed as in Fig. 8.
Percentage of PI-positive cells is shown; 5000–10000 cells per sample
were quantified. B Irgm1−/− MEFs were treated with 2, 3, or 4 mM of
LeuLeuOMe or left untreated for 24 hours. Cells were fixed and stained
with anti-cathepsin B antibody AF965. Average number of cathepsin
B-positive punctae per cell is shown; 50 cells per sample were blind
counted. C WT MEFs and Irgm1−/− MEFs were treated with 200 U/mL
IFN-γ, 3 mM LeuLeuOMe, or left un-treated for 24 hours. Cells were fixed
and stained with anti-cathepsin B antibody. Representative images of
cathepsin B staining and phase contrast are shown. D Quantification of
S9C, showing mean number of cathepsin B punctae per cell; 100 cells
per sample were blind counted and the results of two independent
experiments are shown. (TIF 19085 kb)
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